Verve is lat­est gene edit­ing com­pa­ny to suf­fer set­back, as Ver­tex walks away from pact

Verve Ther­a­peu­tics has not es­caped the doom that seems to be en­gulf­ing the gene edit­ing sec­tor of late. The com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.